Vaccination Roundtable with Experts from Sanofi & Janssen

September 27, 2021
Kevin Kunzmann

Michael Greenberg, MD, MPH, and Rick Nettles, MD, join Lungcast to discuss COVID-19 vaccine development, the 2021-22 flu season, RSV outbreaks, and more respiratory viruses.

With US influenza vaccine rollout in effect and the population working toward 60% fully-vaccinated protection against COVID-19, the discussion of immunization may not be more substantial than it is today.

However, although COVID-19 and flu outbreak risk are the leading preventable threats of focus today, they are only the very beginning of discussion around what’s still needed in respiratory virus protection.

In this episode of Lungcast, American Lung Association (ALA) Chief Medical Officer Albert Rizzo, MD, examines the status and future of respiratory virus immunization with a duo of industry leaders well-versed in the subject.

Michael Greenberg, MD, MPH, Medical Head of Sanofi Pasteur North America, and Rick Nettles, MD, Vice President ofUS Medical Affairs at Janssen Infectious Diseases and Vaccines, weigh in on the most pressing subjects of respiratory virus vaccination—from pediatric COVID-19 studies, to improving adult Tdap vaccine rates and projecting this year’s burden of flu.

Prior to their discussion, Rizzo reviews the history of medical vaccination—a concept first considered in China centuries ago.

Lungcast is a monthly respiratory health podcast series from the ALA, produced by HCPLive.

Subscribe or listen to Lungcast on your favorite platforms:


x